Stempeutics Research Private Limited

Stempeutics is a leading Regenerative Medicine company in Bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. The company's flagship product, Stempeucel® has received market authorization to treat Critical Limb Ischemia – a major unmet medical need in India. It is the FIRST innovative cell therapy based product to get marketing approval in India and Globally. CIPLA, the Indian licensee, has commenced pan-India commercialization. It has the FIRST DCGI approved Cell therapy product for Knee Osteoarthritis being marketed by Alkem. Stempeutics has a product in the Phase 3 stage covering Diabetic Foot Ulcer. Further it is conducting Phase 2 trial in Perianal fistula due to Crohn’s disease. Stempeucel® has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel® has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug for the treatment of CLI due to Buerger’s Disease by the European Medicines Agency (EMA) Another portfolio developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from the stem cell derived Growth Factors/Cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Other products ready for marketing are Trichosera™ for Hair application and Optisera™ for under eye application With a strong pipeline in Cell and Gene therapy products in some of the largest health and personal care segments like OTC Cosmetics (Skin and Hair Care), Osteoarthritis, Diabetes, CLI and PAF Stempeutics is poised to transform the Cell & Gene therapy space with its India First, Global Next approach.

genique lifesciences

Genique is a biomedical company focused on using genomics in conjunction with current diagnostic tools to improve healthcare outcomes

Lab Tech Support

Lab Tech Support helps scientists and laboratory analysts increase uptime, research & testing all while decreasing maintenance and repair cost of analytical instrumentation. Laboratory Service Provider with 20+ years of experience in mass spectrometry repair, maintenance and support. Whether your are located in the United States, Canada, Mexico, or Europe, our Service Engineers are available 24/7!

nova biologics, inc.

NOVA Biologics, Inc. is a global provider of biologic raw material intermediates to clinical laboratories, research organizations, and pharmaceutical and in-vitro manufacturers. We offer a range of serums and plasma, including disease state and patient sample materials. As well as human and animal-derived products for use in cell culture, IVD, and further manufacture of therapeutic injectable products. Nova Biologics, Inc. is dedicated to providing the highest quality biologic raw material intermediates to our diverse customer base in order to help meet the demanding needs and requirements of their organizations. We are committed to establishing strategic, long-term relationships with our valued customers and partners by providing them with secure procurement of products at competitive prices in a timely manner. Our vision is to continue to facilitate supply and manufacturing partnerships allowing NOVA to expand our product and service capabilities. Our products include diagnostic serums and plasma, human serum albumin, human gamma globulin, disease plasmas, clinical samples, and human and animal-based materials. Nova is the sales representative for Octapharma excipient albumin to the biotech and pharmaceutical industry worldwide.

Servatus Ltd

We are a biopharmaceutical research and production company, based on the Sunshine Coast, Queensland. Established in 2012, we research, develop and produce high-quality, innovative, medical grade biopharmaceuticals based on the latest scientific research. Servatus has two drug research platforms: Engineered proteins for the treatment of autoimmune diseases, and microbial biotherapeutics for the treatment of inflammatory conditions and bacterial infections. Our protein research focuses on improving specific characteristics of existing therapeutic proteins. We carefully select proteins with clear clinical utility, and through rational redesign of key features, we improve bioavailbility and biological potency. We then rapidly clone and express the proteins in amounts suitable for clinical use, thus providing faster, more effective treatment of chronic auto immune diseases, such as rheumatoid arthritis and psoriasis, with fewer undesirable side effects. In parallel with our protein work, we also develop live microbial biotherapeutic treatments for microbiome-associated conditions, including but not limited to inflammatory bowel disease (IBD), arthritis, atopic dermatitis, and gastrointestinal infections (for example, C. diff and H.pylori infections). We utilise bacterial strains that have not been widely employed previously, but have demonstrated bioactive properties in the latest scientific research. These bacteria have been shown to inhibit pathogenic bacterial growth and infection, modulate immune responses, and regulate inflammatory signals. Bacterial candidates are developed to act directly at specific sites to treat specific ailments and diseases. Servatus currently holds patents for numerous microbial biotherapeutics and engineered proteins for autoimmune disease treatments Servatus Ltd derives its name from the patron saint St Servatus, a 4th century churchman and diplomat, who was invoked as a saint for his healing powers for a range of ailments. #biotech